Nicox SA (GB:0RCQ)
LSE:0RCQ
0RCQ Stock Chart & Stats
€0.40
>-€0.01(-1.83%)
At close: 4:00 PM EST
€0.40
>-€0.01(-1.83%)
Day’s Range― - ―
52-Week Range€0.21 - €0.65
Previous CloseN/A
Volume120.00
Average Volume (3M)72.86K
Market Cap
€37.85M
Enterprise Value€38.18M
Total Cash (Recent Filing)€11.26M
Total Debt (Recent Filing)€25.79M
Price to Earnings (P/E)―
Beta0.69
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding88,441,770
10 Day Avg. Volume54,119
30 Day Avg. Volume72,863
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)4.11
Price to Sales (P/S)1.78
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.50Price Target Upside275.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet ImprovementAll secured debt was repaid and new unsecured bond financing extended the cash runway, reducing near‑term funding pressure for ongoing development activities.
Clinical Trial ResultsNCX 470 met the primary efficacy endpoint in a second large Phase 3 glaucoma trial and demonstrated faster onset plus stronger pressure‑lowering effect than standard treatments, supporting approval prospects and potential clinician adoption.
Partner Funding And Milestone UpsidePartner Kowa is financing late‑stage development, leading regulatory efforts, and has triggered a milestone payment, leaving Nicox eligible for further submission and sales milestones as well as royalties on net sales.
Bears Say
Commercial Competition RiskAnalyst warns that even if approved, NCX 470 could face limited commercial uptake because the glaucoma market is competitive and gaining market share may be challenging.
Regulatory Approval RiskAnalyst highlights the risk that regulatory approval may not be granted despite positive data, which would materially damage the product’s commercial prospects.
Shareholder Dilution RiskAnalyst cautions that future financing needs could result in shareholder dilution if additional capital is required to complete development or support commercialization.
Nicox SA News
0RCQ FAQ
What was Nicox SA’s price range in the past 12 months?
Nicox SA lowest share price was €0.21 and its highest was €0.65 in the past 12 months.
What is Nicox SA’s market cap?
Nicox SA’s market cap is €37.85M.
When is Nicox SA’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Nicox SA’s earnings last quarter?
Currently, no data Available
Is Nicox SA overvalued?
According to Wall Street analysts Nicox SA’s price is currently Undervalued.
Does Nicox SA pay dividends?
Nicox SA does not currently pay dividends.
What is Nicox SA’s EPS estimate?
Nicox SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Nicox SA have?
Nicox SA has 88,441,770 shares outstanding.
What happened to Nicox SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nicox SA?
Currently, no hedge funds are holding shares in GB:0RCQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nicox SA
Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. The company is also developing NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, an NO-donating Phosphodiesterase-5 inhibitor, which is in preclinical evaluation. It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was incorporated in 1996 and is headquartered in Valbonne, France.
0RCQ Stock 12 Month Forecast
Average Price Target
€1.50
▲(275.00% Upside)